LRH and its agonists have been shown to exert both stimulatory and inhibitory effects on testicular function. In the present study, the dose and length of treatment were tested to determine the appearance of the stimulatory and inhibitory effects of LRH agonist on testicular axis including the three levels. Two doses of an agonist of LRH, 40 and 100 ng/100 g body weight (buserelin, 'agonist'), were administered daily for 1 to 15 days to adult male rats. Control rats received the vehicle only. On day 1, 2, 4, 8 and 15 of treatment, the pituitary, testicular and peripheral levels (weight of accessory sex organs and androgen receptors in ventral prostate) were tested 6 h after the last injection. For the 15 days of treatment with both doses, a stimulatory effect of the 'agonist' was observed on LH and FSH release. A short exposure (1\p=n-\2 days) to the low dose of the 'agonist' had a stimulatory effect on the density of LH/hCG testicular receptors (326 \ m=+-\49 vs control 185 \ m=+-\ 2 1 fmol/mg protein, mean \m=+-\SEM), on the weights of seminal vesicles and ventral prostate and exposure to both doses led to high plasma testosterone levels (13.8 \ m=+-\ 0.5 and 13.7 \ m=+-\0.7 ng/ml, respectively, vs control 2.6 \ m=+-\ 0.3 ng/ml), and to an increased density of nuclear androgen receptors in the ventral prostate (142 \ m=+-\9 and 144 \m=+-\15 fmol/mg protein respectively vs control 97 \ m=+-\ 12 fmol/mg protein). A prolonged exposure (4\p=n-\15 days) to both doses of the 'agonist' had a time-dependent inhibitory effect on the density of LH/hCG testicular receptors, the weight of testes, seminal vesicles and ventral prostate. It had no effects on plasma testosterone levels and on the density of nuclear ardrogen receptors in the ventral prostate. These data show that exposure to low doses of the 'agonist' for a short time leads to a stimulatory effect on the pituitary testicular axis in the adult rat, whereas a more prolonged treatment results into a partial inhibition of this axis affecting first the testicular level then the peripheral level but without decreasing the density of androgen receptors in the ventral prostate.